Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Med Case Rep ; 18(1): 309, 2024 Jul 04.
Article in English | MEDLINE | ID: mdl-38961469

ABSTRACT

BACKGROUND: Hodgkin's lymphoma (HL) is an extremely rare cause of ocular inflammation that is usually not considered in the typical workup of uveitis and other eye diseases. A few cases of ocular inflammation were reported previously showcasing HL with absence of typical symptoms of HL at presentation. Acknowledging the potential ocular inflammation associated with HL can prompt ophthalmologists to broaden their diagnostic approach and collaborate with internal medicine departments to investigate this rare yet significant etiology. CASE PRESENTATION: A 17-year-old Caucasian woman presenting unilateral panuveitis was later diagnosed with HL. The ocular findings were non-necrotizing scleritis, anterior uveitis, vitritis, white/yellowish chorioretinal lesions, papillitis and vasculitis. A left supra-clavicular lymph node biopsy confirmed the diagnosis of nodular sclerosing Hodgkin's lymphoma stage IIB. Other causes of uveitis were excluded. Chemotherapy led to remission of the disease and the ocular lesions became quiescent with persistent pigmented chorioretinal scars. CONCLUSIONS: Hodgkin's lymphoma should be considered in the differential diagnosis of diseases that can occasionally be revealed by unilateral ocular inflammation. A comprehensive, multidisciplinary approach is key to properly assessing such cases.


Subject(s)
Hodgkin Disease , Humans , Hodgkin Disease/diagnosis , Female , Adolescent , Diagnosis, Differential , Scleritis/diagnosis , Scleritis/etiology , Scleritis/drug therapy , Uveitis/diagnosis , Uveitis/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Panuveitis/diagnosis , Panuveitis/drug therapy , Panuveitis/etiology
2.
Int J Mol Sci ; 24(5)2023 Feb 24.
Article in English | MEDLINE | ID: mdl-36901938

ABSTRACT

Proliferative vitreoretinal diseases (PVDs) encompass proliferative vitreoretinopathy (PVR), epiretinal membranes, and proliferative diabetic retinopathy. These vision-threatening diseases are characterized by the development of proliferative membranes above, within and/or below the retina following epithelial-mesenchymal transition (EMT) of the retinal pigment epithelium (RPE) and/or endothelial-mesenchymal transition of endothelial cells. As surgical peeling of PVD membranes remains the sole therapeutic option for patients, development of in vitro and in vivo models has become essential to better understand PVD pathogenesis and identify potential therapeutic targets. The in vitro models range from immortalized cell lines to human pluripotent stem-cell-derived RPE and primary cells subjected to various treatments to induce EMT and mimic PVD. In vivo PVR animal models using rabbit, mouse, rat, and swine have mainly been obtained through surgical means to mimic ocular trauma and retinal detachment, and through intravitreal injection of cells or enzymes to induce EMT and investigate cell proliferation and invasion. This review offers a comprehensive overview of the usefulness, advantages, and limitations of the current models available to investigate EMT in PVD.


Subject(s)
Vitreoretinopathy, Proliferative , Humans , Mice , Rats , Animals , Rabbits , Swine , Vitreoretinopathy, Proliferative/drug therapy , Epithelial-Mesenchymal Transition , Endothelial Cells/metabolism , Retinal Pigment Epithelium/metabolism , Disease Models, Animal
3.
BMJ Open ; 12(6): e058622, 2022 06 01.
Article in English | MEDLINE | ID: mdl-35649616

ABSTRACT

OBJECTIVES: This study aimed to assess the capacities and governance of Lebanon's health system throughout the response to the COVID-19 pandemic until August 2020. DESIGN: A qualitative study based on semi-structured interviews. SETTING: Lebanon, February-August 2020. PARTICIPANTS: Selected participants were directly or indirectly involved in the national or organisational response to the COVID-19 pandemic in Lebanon. RESULTS: A total of 41 participants were included in the study. 'Hardware' capacities of the system were found to be responsive yet deeply influenced by the challenging national context. The health workforce showed high levels of resilience, despite the shortage of medical staff and gaps in training at the early stages of the pandemic. The system infrastructure, medical supplies and testing capacities were sufficient, but the reluctance of the private sector in care provision and gaps in reimbursement of COVID-19 care by many health funding schemes were the main concerns. Moreover, the public health surveillance system was overwhelmed a few months after the start of the pandemic. As for the system 'software', there were attempts for a participatory governance mechanism, but the actual decision-making process was challenging with limited cooperation and strategic vision, resulting in decreased trust and increased confusion among communities. Moreover, the power imbalance between health actors and other stakeholders affected decision-making dynamics and the uptake of scientific evidence in policy-making. CONCLUSIONS: Interventions adopting a centralised and reactive approach were prominent in Lebanon's response to the COVID-19 pandemic. Better public governance and different reforms are needed to strengthen the health system preparedness and capacities to face future health security threats.


Subject(s)
COVID-19 , Influenza, Human , COVID-19/epidemiology , Government Programs , Humans , Influenza, Human/epidemiology , Pandemics , Policy Making
SELECTION OF CITATIONS
SEARCH DETAIL
...